Literature DB >> 28981994

Contributors to the substantial variation in on-treatment testosterone levels in men receiving transdermal testosterone gels in randomized trials.

S Bhasin1, T G Travison1, L O'Brien2, J MacKrell2, V Krishnan2, H Ouyang2, K Pencina1, S Basaria1.   

Abstract

There is substantial inter-individual variability in serum testosterone levels in hypogonadal men treated with testosterone gels. We aimed to elucidate participant-level factors that contribute to inter-individual variability in testosterone levels during testosterone therapy. An exploratory aim was to determine whether polymorphisms in genes encoding testosterone-metabolizing enzymes could explain the variation in on-treatment testosterone concentrations in men who were randomized to testosterone arm in TOM Trial. We used data from three randomized trials that used 1% transdermal testosterone gels and had testosterone levels measured 2-4 weeks after randomization for dose adjustment: Testosterone in Older Men with Mobility Limitation (TOM), Effects of Testosterone on Pain Perception (TAP), and Effects of Testosterone on Atherosclerosis Progression (TEAAM). Forty-seven percent, 38%, and 9% of participants in TAP, TEAAM, and TOM trials, respectively, failed to raise testosterone levels >400 ng/dL; 6, 8, and 30% of participants had on-treatment testosterone levels >1000 ng/dL. Even after dose adjustment, there was substantial variation in on-treatment levels at subsequent study visits. Baseline characteristics (age, height, weight, baseline testosterone, SHBG, hematocrit, and creatinine) accounted for only a small fraction of the variance (<8%). Polymorphisms in SHBG and AKR1C3 genes were suggestively associated with on-treatment testosterone levels. To conclude, baseline participant characteristics account for only a small fraction of the variance in on-treatment testosterone levels investigated. Multiple dose titrations are needed to maintain on-treatment testosterone levels in the target range. The role of SHBG and AKR3C1 polymorphisms as contributors to variations in on-treatment testosterone levels should be investigated.
© 2017 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  androgens; genotype; testosterone; variation

Mesh:

Substances:

Year:  2017        PMID: 28981994     DOI: 10.1111/andr.12428

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  5 in total

1.  Klotho Polymorphism in Association With Serum Testosterone and Knee Strength in Women After Testosterone Administration.

Authors:  Lena Ekström; Jona Elings Knutsson; Christina Stephanou; Angelica Lindén Hirschberg
Journal:  Front Physiol       Date:  2022-05-03       Impact factor: 4.755

2.  Effect of Dose and 5α-Reductase Inhibition on the Circulating Testosterone Metabolite Profile of Men Administered Oral Testosterone.

Authors:  Abdul Basit; John K Amory; Bhagwat Prasad
Journal:  Clin Transl Sci       Date:  2018-06-19       Impact factor: 4.689

3.  Genetic predictors of testosterone and their associations with cardiovascular disease and risk factors: A Mendelian randomization investigation.

Authors:  C Mary Schooling; Shan Luo; Shiu Lun Au Yeung; Deborah J Thompson; Savita Karthikeyan; Thomas R Bolton; Amy M Mason; Erik Ingelsson; Stephen Burgess
Journal:  Int J Cardiol       Date:  2018-05-18       Impact factor: 4.164

Review 4.  Testosterone in men with hypogonadism and transgender males: a systematic review comparing three different preparations.

Authors:  Milou Cecilia Madsen; Martin den Heijer; Claudia Pees; Nienke R Biermasz; Leontine E H Bakker
Journal:  Endocr Connect       Date:  2022-07-25       Impact factor: 3.221

5.  Health Outcomes Among Long-term Opioid Users With Testosterone Prescription in the Veterans Health Administration.

Authors:  Guneet K Jasuja; Omid Ameli; Joel I Reisman; Adam J Rose; Donald R Miller; Dan R Berlowitz; Shalender Bhasin
Journal:  JAMA Netw Open       Date:  2019-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.